Buying pressure lifts Hims & Hers Health stock higher in today's trading

Traders Union
All News
Financial News
Hims & hers health gains 2.55% today

Highlights

Hims & Hers secured rights to FDA-approved GLP-1 drugs Wegovy and Ozempic after settling with Novo Nordisk, expanding its obesity treatment offerings.
The company announced plans to acquire Eucalyptus for up to $1.15 billion, increasing international presence across Australia, Japan, the UK, Germany, and Canada.
Despite strong recent momentum, technical signals show short-term overbought conditions with likely sideways trading in the $28.61–$36.98 range and a higher probability of near-term pullback.

Revenue slowdown and GLP-1 deals drive sentiment shift

Hims & Hers Health is preparing to release first quarter earnings, with consensus revenue estimates between $616 million and $619 million, signaling a deceleration from the previous year's pace. The company recently settled with Novo Nordisk, securing rights to distribute FDA-approved GLP-1 medications Wegovy and Ozempic on its digital platform. Hims & Hers has also ended advertising for compounded GLP-1 drugs in response to regulatory review and announced an agreement to acquire Eucalyptus for up to $1.15 billion, expanding its reach into Australia, Japan, the UK, Germany, and Canada.

Anton Kharitonov, expert at Traders Union, views the strong momentum in Hims & Hers Health as unsustainable. He notes the stock remains well below its 200-day moving average and shows multiple overbought technical signals. Sentiment may be getting ahead of fundamentals, especially as top-line growth decelerates and regulatory questions persist after the GLP-1 settlement. The acquisition of Eucalyptus adds expansion risk and potential integration hurdles. "Despite recent gains, I do not see a durable bullish setup while long-term signals and fundamentals appear fragile here."

Viktoras Karapetjanc, expert at Traders Union, sees multiple opportunities opening for Hims & Hers Health after its Novo Nordisk settlement and planned Eucalyptus buyout. He believes global expansion and direct access to FDA-approved GLP-1 drugs will accelerate platform adoption, even if short-term technicals appear stretched. Karapetjanc highlights the constructive sentiment reflected in the strong price action and recent news flow. "I remain confident in the bullish structure and expect further growth as the company executes on expansion and regulatory clarity improves."

Jainam Mehta, market strategist, notes that HIMS trades above key short-term averages and shows strong momentum, but warns divergence in oscillators signals risk of consolidation. He sees scope for tactical trading in the $28.61 to $36.98 window, with a breakout above $30 as a possible trigger for aggressive longs. Mehta suggests keeping stops tight as fundamentals are mixed and the stock nears a resistance cluster. "A move above $30 could set up a quick upside play, but traders should be ready to pivot if selling resumes below near-term support."

Bullish momentum meets overbought signals amid waning intraday strength

Momentum remains strong as highlighted by a bullish MACD and an elevated Average Directional Index (ADX), although the Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) point to overbought conditions. Bull/Bear Power (BBP) shows clear buyer dominance with a value of 1.49, also marking overbought territory. The daily move is positive, with the stock up $0.72 or 2.55% after an upside gap of about $1.01 on the open. The current price is near the low of today’s range and intraday volatility stands at 0.69%. Intraday dynamics show mild pressure after the open, contrasting slightly with the strong undercurrent of momentum, which hints at potential for further short-term consolidation as oscillators begin to diverge from pure bullishness.

Earlier, analysts noted that Hims & Hers Health was likely to consolidate amid mixed technical signals and limited prospects for a decisive breakout. The latest action—driven by both anticipated earnings and new strategic initiatives—reinforces this sideways bias, with traders advised to monitor for a confirmed close above the $30 level or renewed downside if support at $28.61 fails.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.